{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-011177","form_type":"8-K","ticker":"TMCI","cik":"0001630627","company_name":"TREACE MEDICAL CONCEPTS, INC.","filed_at":"2026-01-13T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.688674+00:00","generated_at":"2026-05-16T10:40:23.094452+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Treace Medical Q4 2025 preliminary revenue falls ~9% YoY; full year in line with guidance","bullets":["Q4 2025 revenue $62.1M-$62.5M, down ~9% YoY at midpoint.","Full-year 2025 revenue $212.3M-$212.7M, ~2% YoY growth, in line with $211M-$213M guidance.","Added ~202 new active surgeons in 2025; total active surgeons ~3,337 (+6%).","Not issuing FY 2026 guidance now; will provide during Q4 earnings call on Feb 26, 2026.","CEO cites headwinds from broader economic conditions, softer consumer sentiment, product mix shift."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-011177","json":"https://secwatch.observer/filing/0001193125-26-011177.json","markdown":"https://secwatch.observer/filing/0001193125-26-011177.md","text":"https://secwatch.observer/filing/0001193125-26-011177.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1630627/000119312526011177/0001193125-26-011177-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1630627/000119312526011177/tmci-20260113.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T10:40:23.094452+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}